As of Aug 31
| +0.06 / +0.73%|
The 5 analysts offering 12-month price forecasts for Regulus Therapeutics Inc have a median target of 27.00, with a high estimate of 42.00 and a low estimate of 15.00. The median estimate represents a +224.13% increase from the last price of 8.33.
The current consensus among 6 polled investment analysts is to Buy stock in Regulus Therapeutics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.